The DOI matches its Crossref record; 213 of the 213 references it cites were found in a registry or an index.
EFNS/MDS‐ES recommendations for the diagnosis of Parkinson's disease
Open accessAbstract
Background: A Task Force was convened by the EFNS/MDS‐ES Scientist Panel on P arkinson's disease (PD) and other movement disorders to systemically review relevant publications on the diagnosis of PD. Methods: Following the EFNS instruction for the preparation of neurological diagnostic guidelines, recommendation levels have been generated for diagnostic criteria and investigations. Results: For the clinical diagnosis, we recommend the use of the Q ueen S quare B rain B ank criteria (Level B). Genetic testing for specific mutations is recommended on an individual basis (Level B), taking into account specific features (i.e. family history and age of onset). We recommend olfactory testing to differentiate PD from other parkinsonian disorders including recessive forms (Level A). Screening for pre‐motor PD with olfactory testing requires additional tests due to limited specificity. Drug challenge tests are not recommended for the diagnosis in de novo parkinsonian patients. There is an insufficient evidence to support their role in the differential diagnosis between PD and other parkinsonian syndromes. We recommend an assessment of cognition and a screening for REM sleep behaviour disorder, psychotic manifestations and severe depression in the initial evaluation of suspected PD cases (Level A). Transcranial sonography is recommended for the differentiation of PD from atypical and secondary parkinsonian disorders (Level A), for the early diagnosis of PD and in the detection of subjects at risk for PD (Level A), although the technique is so far not universally used and requires some expertise. Because specificity of TCS for the development of PD is limited, TCS should be used in conjunction with other screening tests. Conventional magnetic resonance imaging and diffusion‐weighted imaging at 1.5 T are recommended as neuroimaging tools that can support a diagnosis of multiple system atrophy (MSA) or progressive supranuclear palsy versus PD on the basis of regional atrophy and signal change as well as diffusivity patterns (Level A). DaTscan SPECT is registered in E urope and the U nited S tates for the differential diagnosis between degenerative parkinsonisms and essential tremor (Level A). More specifically, DaTscan is indicated in the presence of significant diagnostic uncertainty such as parkinsonism associated with neuroleptic exposure and atypical tremor manifestations such as isolated unilateral postural tremor. Studies of [123 I]MIBG/SPECT cardiac uptake may be used to identify patients with PD versus controls and MSA patients (Level A). All other SPECT imaging studies do not fulfil registration standards and cannot be recommended for routine clinical use. At the moment, no conclusion can be drawn as to diagnostic efficacy of autonomic function tests, neurophysiological tests and positron emission tomography imaging in PD. Conclusions: The diagnosis of PD is still largely based on the correct identification of its clinical features. Selected investigations (genetic, olfactory, and neuroimaging studies) have an ancillary role in confirming the diagnosis, and some of them could be possibly used in the near future to identify subjects in a pre‐symptomatic phase of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–213 of 213
Dodel, R. C., H�ffken, H., Möller, J. C., Bornschein, B., Klockgether, T., Behr, T. M., Oertel, W. H., & Siebert, U. (2003) · Movement Disorders · doi:10.1002/mds.10580 · Cited by 33
Self-citationIto, S., Shirai, W., & Hattori, T. (2007) · Movement Disorders · doi:10.1002/mds.21329 · Cited by 31
Transcranial Sonography in Huntington’S Disease
Krogias, C., Eyding, J., & Postert, T. (2010) · International review of neurobiology · doi:10.1016/s0074-7742(10)90017-2 · Cited by 25
Barsottini, O. G. P., Ferraz, H. B., Maia, A. C. M., da Silva, C. J., & da Rocha, A. J. (2007) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2006.12.011 · Cited by 25
Tachibana, H., Takeda, M., & Sugita, M. (1989) · International Journal of Neuroscience · doi:10.3109/00207458908986210 · Cited by 24
Transcranial magnetic stimulation for differential diagnostics in patients with parkinsonism
Morita, Y., Osaki, Y., & Doi, Y. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00988.x · Cited by 24
Okuda, B., Tachibana, H., Kawabata, K., Takeda, M., & Sugita, M. (1995) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199509020-00002 · Cited by 20
TCS in Monogenic Forms of Parkinson’s Disease
Brockmann, K., & Hagenah, J. M. (2010) · International review of neurobiology · doi:10.1016/s0074-7742(10)90011-1 · Cited by 12
The cold hand sign in multiple system atrophy: skin perfusion revisited
Pietzarka, K., Reimann, M., Schmidt, C., Herting, B., Schöls, L. J., Reichmann, H., Berg, D., Schrader, C., & Ziemssen, T. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0375-x · Cited by 12
Self-citationImaging for early differential diagnosis of parkinsonism
Antonini, A. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70360-6 · Cited by 10
Self-citationNeurophysiologie de la dégénérescence corticobasale
Tyvaert, L., Cassim, F., Derambure, P., & Defebvre, L. (2007) · Revue Neurologique · doi:10.1016/s0035-3787(07)91460-5 · Cited by 6
Increased activity of surviving locus ceruleus neurons in Alzheimer's disease
Moser (1999) · Pure Amsterdam UMC · doi:10.1002/1531-8249(199901)45:1
(2002) · PubMed
Cited by
Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease
Turner, M. D., Nedjai, B., Hurst, T., & Pennington, D. J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.05.014 · Cited by 2,162
Non-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
Gut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968
Challenges in the diagnosis of Parkinson's disease
Tolosa, E., Garrido, A., Scholz, S. W., & Poewe, W. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00030-2 · Cited by 1,874
Self-citationBalestrino, R., & Schapira, A. H. V. (2020) · European Journal of Neurology · doi:10.1111/ene.14108 · Cited by 1,508
Metadata
- Authors
- Berardelli, A., Wenning, G. K., Antonini, A., Berg, D., Bloem, B. R., Bonifati, V., Brooks, D., Burn, D. J., Colosimo, C., Fanciulli, A., Ferreira, J., Gasser, T., Grandas, F., Kanovsky, P., Kostic, V., Kulisevsky, J., Oertel, W., Poewe, W., Reese, J. ‐., Relja, M., Ruzicka, E., Schrag, A., Seppi, K., Taba, P., & Vidailhet, M.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2012-12-22
- Volume
- 20
- Issue
- 1
- Pages
- 16-34
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W2045452241
- Cited by
- 489
- References
- 213
- FWCI
- 17.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.